Sterile Injectable Manufacturing: SOP for Container Closure Integrity Testing – V 2.0
Standard Operating Procedure for Container Closure Integrity Testing
| Department |
Sterile Injectable Manufacturing |
| SOP No. |
SOP/SIM/070/2025 |
| Supersedes |
SOP/SIM/070/2022 |
| Page No. |
Page 1 of 13 |
| Issue Date |
18/06/2025 |
| Effective Date |
20/06/2025 |
| Review Date |
18/06/2026 |
1. Purpose
This SOP outlines the procedure for performing Container Closure Integrity Testing (CCIT) on sterile injectable pharmaceutical products to verify the integrity of packaging systems and ensure product sterility throughout its shelf life.
2. Scope
This procedure applies to all finished injectable products packaged in ampoules, vials, or prefilled syringes at the
sterile manufacturing facility.
3. Responsibilities
- QC Analyst: Conducts CCIT and records the results.
- QC Reviewer: Reviews data for compliance and correctness.
- QA Officer: Verifies integrity test results prior to batch release.
4. Accountability
The Head of Quality Control is accountable for ensuring the integrity of the container closure system through validated CCIT methods.
5. Procedure
5.1 Sampling
- Collect samples from each batch as per sampling plan (refer Annexure-1: Sample Log).
- Include samples from the beginning, middle, and end of the filling process.
5.2 Test Methods
- Use any of the following validated techniques based on product and packaging type:
- Vacuum Decay Method
- Helium Leak Detection
- High Voltage Leak Detection (HVLD)
- Dye Ingress Test
- Ensure all equipment used is calibrated and validated before use (see Annexure-2: Equipment Calibration Log).
5.3 Execution of CCIT
- Inspect each sample using the chosen method according to the validated SOPs.
- For HVLD:
- Connect the syringe/vial to the HVLD system.
- Apply voltage and record any current leakage.
- A value above set threshold indicates failure.
- For dye ingress:
- Submerge samples in 0.1% methylene blue solution and apply vacuum.
- Inspect for dye penetration after specified hold time.
- Document all observations in Annexure-3: CCIT Results Sheet.
5.4 Acceptance Criteria
- All samples must pass CCIT without leak detection, dye ingress, or voltage current beyond limit.
- If any sample fails, follow deviation and batch investigation procedures.
5.5 Handling Failures
- Isolate failed sample and inform QA.
- Initiate root cause investigation and evaluate impact on batch disposition.
- Record investigation in Annexure-4: CCIT Failure Report.
6. Abbreviations
- CCIT: Container Closure Integrity Testing
- HVLD: High Voltage Leak Detection
- QA: Quality Assurance
- QC: Quality Control
- SOP: Standard Operating Procedure
7. Documents
- Sample Log – Annexure-1
- Equipment Calibration Log – Annexure-2
- CCIT Results Sheet – Annexure-3
- CCIT Failure Report – Annexure-4
8. References
- USP <1207> Container Closure Integrity Testing
- ICH Q8 – Pharmaceutical Development
- WHO TRS 996 – Annex 6
9. SOP Version
Version: 2.0
10. Approval Section
|
Prepared By |
Checked By |
Approved By |
| Signature |
|
|
|
| Date |
|
|
|
| Name |
|
|
|
| Designation |
QC Analyst |
QA Executive |
Head QA |
| Department |
Quality Control |
Quality Assurance |
Quality Assurance |
11. Annexures
Annexure-1: Sample Log
| Date |
Product |
Batch No. |
Sampled By |
Remarks |
| 17/06/2025 |
Diclofenac Injection |
DFC-0625-B |
Anil Sharma |
Start, mid, end samples |
Annexure-2: Equipment Calibration Log
| Equipment ID |
Type |
Calibration Date |
Calibrated By |
Remarks |
| HVLD-01 |
HV Leak Detector |
01/06/2025 |
Rajesh Kumar |
Calibrated |
Annexure-3: CCIT Results Sheet
| Sample ID |
Method |
Result |
Tested By |
Remarks |
| DFC-0625-B-01 |
HVLD |
Pass |
Sunita Reddy |
— |
Annexure-4: CCIT Failure Report
| Sample ID |
Failed Method |
Description |
Action Taken |
Reported By |
| DFC-0625-B-07 |
Dye Ingress |
Blue dye detected |
Sample quarantined |
Vinay Pawar |
Revision History
| Revision Date |
Revision No. |
Details |
Reason |
Approved By |
| 01/01/2022 |
1.0 |
Initial issue |
New SOP |
QA Head |
| 18/06/2025 |
2.0 |
Added HVLD protocol and updated annexures |
Annual Review |
QA Head |